Comparison of adverse effects following immunisation degree after the administration COVID-19 vaccine of different platforms
INTRODUCTION: Vaccination is an effective way to overcome the spread of Coronavirus Disease 19 (COVID-19). However, it can give rise to adverse event following immunisation (AEFI). AEFI is an important aspect that is assessed in vaccine safety standards. It is assumed that different vaccine platforms can give rise to different degrees of AEFI severity, but so far there have been no studies that discuss the differences in the degree of AEFI on each type of COVID- 19 vaccine platform.
AIM: Evaluate the differences in the degree of AEFI on each type of COVID-19 vaccine platform.
MATERIALS AND METHODS: The research used a quantitative analytical observational design with a cross sectional approach. Data collection from participants was carried out by filling out questionnaires. The collected data was tabulated and statistical analysis was carried out.
RESULTS: A total of 217 respondents who received three doses of vaccine participated in the study. Of the 651 vaccine doses studied, the results showed that there were significant differences in the degree of AEFI between the three types of vaccine platforms. The degree of AEFI was significantly different (p < 0.05) between each type of vaccine platform, with the degree of AEFI starting from the lowest, namely inactivated vaccine, then viral vector vaccine and the highest was nucleic acid vaccine.
CONCLUSION: The degree of AEFI differs significantly between each COVID-19 vaccine platform. The degree of AEFI, from the mildest to the most severe, was inactivated vaccine, viral vector vaccine and nucleic acid vaccine. No serious AEFI was reported.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
The Medical journal of Malaysia - 79(2024), 2 vom: 29. März, Seite 124-127 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bermawi, B [VerfasserIn] |
|---|
| Themen: |
COVID-19 Vaccines |
|---|
| Anmerkungen: |
Date Completed 01.04.2024 Date Revised 01.04.2024 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM370434439 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370434439 | ||
| 003 | DE-627 | ||
| 005 | 20240403000722.0 | ||
| 007 | tu | ||
| 008 | 240331s2024 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1361.xml |
| 035 | |a (DE-627)NLM370434439 | ||
| 035 | |a (NLM)38553914 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bermawi, B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of adverse effects following immunisation degree after the administration COVID-19 vaccine of different platforms |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2024 | ||
| 500 | |a Date Revised 01.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Vaccination is an effective way to overcome the spread of Coronavirus Disease 19 (COVID-19). However, it can give rise to adverse event following immunisation (AEFI). AEFI is an important aspect that is assessed in vaccine safety standards. It is assumed that different vaccine platforms can give rise to different degrees of AEFI severity, but so far there have been no studies that discuss the differences in the degree of AEFI on each type of COVID- 19 vaccine platform | ||
| 520 | |a AIM: Evaluate the differences in the degree of AEFI on each type of COVID-19 vaccine platform | ||
| 520 | |a MATERIALS AND METHODS: The research used a quantitative analytical observational design with a cross sectional approach. Data collection from participants was carried out by filling out questionnaires. The collected data was tabulated and statistical analysis was carried out | ||
| 520 | |a RESULTS: A total of 217 respondents who received three doses of vaccine participated in the study. Of the 651 vaccine doses studied, the results showed that there were significant differences in the degree of AEFI between the three types of vaccine platforms. The degree of AEFI was significantly different (p < 0.05) between each type of vaccine platform, with the degree of AEFI starting from the lowest, namely inactivated vaccine, then viral vector vaccine and the highest was nucleic acid vaccine | ||
| 520 | |a CONCLUSION: The degree of AEFI differs significantly between each COVID-19 vaccine platform. The degree of AEFI, from the mildest to the most severe, was inactivated vaccine, viral vector vaccine and nucleic acid vaccine. No serious AEFI was reported | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Nucleic Acid-Based Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Inactivated |2 NLM | |
| 700 | 1 | |a Donastin, A |e verfasserin |4 aut | |
| 700 | 1 | |a Sari, N D K |e verfasserin |4 aut | |
| 700 | 1 | |a Kurniasari, D W |e verfasserin |4 aut | |
| 700 | 1 | |a Adriansyah, A A |e verfasserin |4 aut | |
| 700 | 1 | |a Ferdiansyah, M A |e verfasserin |4 aut | |
| 700 | 1 | |a Rofananda, I F |e verfasserin |4 aut | |
| 700 | 1 | |a Surya, P A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Medical journal of Malaysia |d 1972 |g 79(2024), 2 vom: 29. März, Seite 124-127 |w (DE-627)NLM000278386 |x 0300-5283 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2024 |g number:2 |g day:29 |g month:03 |g pages:124-127 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2024 |e 2 |b 29 |c 03 |h 124-127 | ||